4
Changes in Ownership
Acrivon Therapeutics, Inc. Filed Acc 0001104659-22-120780
Director bought 3,389,500 shares at $12.50 ($42,368,750)
- Director acquired 1,421,008 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
RA CAPITAL MANAGEMENT, L.P. · Director
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2022-11-17 | Conversion : show line 1 in the form | +994,706 | 994,706 | I | ||
| 2022-11-17 | Purchase : show line 2 in the form | +3,389,500 | $12.50 | $42,368,750 | 4,384,206 | I |
| 2022-11-17 | Conversion : show line 3 in the form | +426,302 | 426,302 | I | ||
| Open-market purchases · 3,389,500 sh · avg $12.50 · $42,368,750 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2022-11-17 | Conversion : show line 4 in the form Series B Preferred Stock | −2,452,947 | 0 | I |
| 2022-11-17 | Conversion : show line 5 in the form Series B Preferred Stock | −1,051,263 | 0 | I |
Loading xslF345X03/tm2231060-1_4seq1.xml…